Inspection Record

Lupin Limited — FDA 483 Findings

US FDAInspected 2023-03-29Published 2023-04-14 10 findingsDeviation, CAPA, and investigationEquipment and facilityComplaint and recall handlingQuality unit oversightLaboratory and QC controlsAseptic processing and sterility assuranceComputer system validationTraining and personnel

Inspectors Yvins DezanThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Deviation, CAPA, and investigation

Investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other diug products that may have been associated with the specific failure or discrepancy.

2Equipment and facility

Equipment for adequate control over air pressure, humidity, temperature is not provided when appropriate for the manufacture, processing, packing or holding ofa diug product.

3Complaint and recall handling

(Repeat) Written records of investigation of a dtug complaint do not include the findings of the investigation and the follow-up.

4Deviation, CAPA, and investigation

(Repeat) There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been ah-eady distributed.

5Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not [in writing] [fully followed].

6Laboratory and QC controls

Laborato1y controls do not include the establishment ofscientifically sound and appropriate specifications, test procedures designed to assure that components, drug products confo1m to appropriate standards of identity, strength, quality and purity.

7Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of dm g products purporting to be sterile are not established, written, or followed.

8Equipment and facility

Substances required for equipment operations such as lubricants and coolants come in contact with diu g product containers, closures, dmg product so as to alter the safety, identity, strength, quality, or purity of the dmg product beyond the official or other established requirements.

9Computer system validation

(Repeat) Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.

10Training and personnel

(Repeat) Employees engaged in the manufacture, processing, packing and holding of a drng product lack the training required to perfo1m their assigned functions.

About this record

Extracted automatically from the document US FDA published on 2023-04-14. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Lupin Limited company profile — full history US FDA documents, 2023 Go to Findings search